

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included and are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

acalabrutinib	0	Monotherapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) not previously treated with a BTK inhibitor.	Not routinely available as not recommended for use in NHSScotland	19/10/2026
Calquence				
SMC2985				
acoramidis	0	Treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).	Not routinely available as not recommended for use in NHSScotland	19/10/2026
Beyontra				
SMC2986				
Arsenic trioxide, all-trans retinoic acid (ATRA [tretinoin])	0	Treatment of high-risk acute promyelocytic leukaemia	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:	19/10/2026
NCMAG127			07/12/2026	
aspirin	0	Adjuvant treatment of resected colorectal cancers with somatic PI3K pathway alterations.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:	19/10/2026
generically available		- Stage I to III rectal cancers - Stage II to III colon cancers	07/12/2026	
NCMAG129				

Medicine	Condition being treated	NHSGGC Decision	Date of decision
atidarsagene autotemcel Libmeldy® SMC2886	Treatment of metachromatic leukodystrophy (MLD) characterized by biallelic mutations in the arylsulfatase A (ARSA) gene leading to a reduction of the ARSA enzymatic activity: - in children with late infantile or early juvenile forms, without clinical manifestations of the disease, - in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.	Routinely available in line with national guidance	19/10/2026
atogepant Aquipta SMC2934	Acute treatment of migraine with or without aura in adults.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
belantamab mafodotin Blenrep SMC2727	in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
benralizumab Fasenra® SMC2870	Add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/02/2027	19/10/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
betula verrucosa Itulazax SMC2904	0 Adults and children (5 years or older) for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous. It is indicated in patients with a clinical history of symptoms despite use of symptom-relieving medication and a positive test of sensitisation to a member of the birch homologous group (skin prick test and/or specific IgE).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/02/2027	19/10/2026
cabozantinib Cabozantinib Ipsen® SMC2967	0 Treatment of adult patients with unresectable or metastatic, well-differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues.	Routinely available in line with local or regional guidance	19/10/2026
cabozantinib SMC2754	0 Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
capivasertib Truqap® SMC2930	0 In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine based regimen.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
capsaicin Qutenza® SMC2861	0 Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
depemokimab Exdensur® SMC2970	0 Add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.	Not routinely available as not recommended for use in NHSScotland	19/10/2026
Dermatophagoides pteronyssinus, Dermatophagoides farinae Acarizax® SMC2885	0 Treatment of adult patients (18-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific immunoglobulin E (IgE) with at least one of the following conditions: • persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication • house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/02/2027	19/10/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
deuruxolitinib Leqselvi SMC2968	Treatment of adult patients with severe alopecia areata. 0	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
dostarlimab Jemperli® SMC2953	In combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. 0	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
elacestrant Korserdu® SMC2933	Monotherapy for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor. 0	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
epcoritamab Tepkinly® SMC2881	Monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy 0	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
exagamglogene autotemcel Casgevy® SMC2852	Treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises who have the β S/ β S, β S/ β + or β S/ β 0 genotype, for whom haematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related haematopoietic stem cell donor is not available.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
fezolinetant Veoza® SMC2898	Treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/02/2027	19/10/2026
glofitamab Columvi® SMC2846	In combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).	Routinely available in line with local or regional guidance	19/10/2026
hydrocortisone Efmody® SMC2971	In adolescents aged 12 years and over and adults for the treatment of adrenal insufficiency (AI).	Not routinely available as not recommended for use in NHSScotland	19/10/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
inavolisib Itovebi SMC2902	In combination with palbociclib and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. Patients previously treated with a CDK 4/6 inhibitor in the (neo)adjuvant setting should have had an interval of at least 12 months between termination of CDK 4/6 inhibitor treatment and the detection of recurrence. In pre/perimenopausal women and in men, endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.	Not routinely available as not recommended for use in NHSScotland	19/10/2026
levodopa, carbidopa, entacapone Lecigon® SMC2876	Treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
lisocabtagene maraleucel Breyanzi® SMC2972	Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), after two or more lines of systemic therapy.	Not routinely available as not recommended for use in NHSScotland	19/10/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
lorlatinib Lorviqua® SMC2867	0 Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after prior treatment with an ALK inhibitor.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
mirvetuximab soravtansine Elahere SMC2892	0 Monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
nusinersen Spinraza SMC2959	0 The treatment of 5q Spinal Muscular Atrophy (SMA).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/02/2027	19/10/2026
nusinersen Spinraza® SMC2877	0 Treatment of 5q Spinal Muscular Atrophy	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/02/2027	19/10/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
obinutuzumab Gazyvaro SMC2903	0 In combination with mycophenolate mofetil (MMF), for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis (LN).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/02/2027	19/10/2026
palopecteriparatide Yorvipath SMC2887	0 The treatment of adults with chronic hypoparathyroidism	Not routinely available as not recommended for use in NHSScotland	19/10/2026
Pazopanib Votrient NCMAG128	0 For the treatment of adult patients with selective sub-types of soft tissue sarcoma who have received prior chemotherapy for metastatic disease or who have progressed within 12 months of (neo) adjuvant therapy.	Routinely available in line with local or regional guidance	19/10/2026
pembrolizumab Keytruda® SMC2907	0 Monotherapy for the treatment of resectable locally advanced head and neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumours express PD-L1 with a CPS≥ 1.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
ribociclib Kisqali® SMC2803	0 In combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
seladelpar Livdelzi® SMC2946	0 Treatment of primary biliary cholangitis (PBC), including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
selumetinib Koselugo SMC2987	0 Monotherapy for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with neurofibromatosis type 1 (NF1).	Not routinely available as not recommended for use in NHSScotland	19/10/2026
semaglutide Wegovy® SMC2872	0 As an adjunct to a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥27 kg/m2)	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/02/2027	19/10/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Semaglutide Wegovy SMC2497	0 An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of • $\geq 30 \text{ kg/m}^2$ (obesity), or • $\geq 27 \text{ kg/m}^2$ to $< 30 \text{ kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
semaglutide Wegovy SMC2988	0 As an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of • $\geq 30 \text{ kg/m}^2$ (obesity), or • $\geq 27 \text{ kg/m}^2$ to $< 30 \text{ kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity	Not routinely available as not recommended for use in NHSScotland	19/10/2026
sodium zirconium cyclosilicate Lokelma® SMC2884	0 Treatment of hyperkalaemia in adult patients	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
sotatercept Winrevair® SMC2973	0 In combination with other pulmonary arterial hypertension (PAH) therapies for the treatment of PAH in adult patients with WHO Functional Class (FC) IV.	Not routinely available as not recommended for use in NHSScotland	19/10/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
tebentafusp Kimmtrak® SMC2910	0 Monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma	Routinely available in line with local or regional guidance	19/10/2026
tirzepatide Mounjaro® SMC2653	0 For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
toripalimab Loqtorzi® SMC2974	0 In combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.	Not routinely available as not recommended for use in NHSScotland	19/10/2026
upadacitinib Rinvoq® SMC2879	0 Treatment of giant cell arteritis in adult patients	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/02/2027	19/10/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
vutrisiran Amvuttra SMC2900	0 The treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM)	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
zilucoplan Zilbrysq® SMC2955	0 As an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026
zolbetuximab Vyloy® SMC2839	0 In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	19/10/2026